Search

Displaying results 3661 - 3670 of 8697 in total
  1. Drug

    Flunarizine

    go.drugbank.com/drugs/DB04841
    ApprovedInvestigational

    It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  2. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  3. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. … In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as

    Categories: Estrogen Receptor Modulators, Selective Estrogen Receptor Modulators
  4. Drug

    Prochlorperazine

    go.drugbank.com/drugs/DB00433
    ApprovedInvestigationalVet approved

    Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Polythiazide

    go.drugbank.com/drugs/DB01324
    Approved

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826)

    Categories: Antihypertensive Agents Indicated for Hypertension
  6. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [A273993,A273998] As opposed to [lanadelumab], another prophylactic agent for HAE that targets kallikrein, garadacimab targets activated factor XII, the first factor in the contact system responsible for … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.

  7. Drug

    Calusterone

    go.drugbank.com/drugs/DB01564
    ExperimentalIllicit

    A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.

  8. Drug

    Diacerein

    go.drugbank.com/drugs/DB11994
    ApprovedInvestigationalWithdrawn

    Diacerein is under investigation for the treatment of Insulin Resistance, Diabetes Mellitus (Type 2), and Diabetes-Related Complications. … It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea [L780].

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  9. Drug

    Florbetaben F-18

    go.drugbank.com/drugs/DB09148
    ApprovedInvestigational

    Florbetaben is a fluorine-18 (18F)-labeled stilbene derivative used for Positron Emission Tomography (PET) imaging of the brain. … This radioactive diagnostic drug is used for the non-invasive detection of the density of beta-amyloid plaques in the brain of adult patients with cognitive impairment.[A18514, L53703]

  10. Drug

    Viomycin

    go.drugbank.com/drugs/DB06827
    Approved

    Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was deri...

    Categories: Drugs for Treatment of Tuberculosis